IL2 and cancer: Although FDA approved two recombinant cytokines, Interferon (IFNA) and Interleukin-2 (IL-2), as cancer immunotherapy drugs, the application of cytokines in immunotherapy still encounters many barriers and limitations, due to their pleiotropy, off-target effects, and short half-life in circulation1.